Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Other Operating Expenses (2022 - 2025)

Axsome Therapeutics' Other Operating Expenses history spans 4 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 78.93% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $51.4 million, down 24.24%, while the annual FY2025 figure was $51.4 million, 24.24% down from the prior year.
  • Other Operating Expenses for Q4 2025 was $4.9 million at Axsome Therapeutics, down from $26.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $52.2 million in Q4 2023 and bottomed at -$61502.0 in Q1 2023.
  • The 4-year median for Other Operating Expenses is $8.0 million (2023), against an average of $12.8 million.
  • The largest annual shift saw Other Operating Expenses soared 90170.07% in 2023 before it tumbled 78.93% in 2025.
  • A 4-year view of Other Operating Expenses shows it stood at -$57946.0 in 2022, then skyrocketed by 90170.07% to $52.2 million in 2023, then plummeted by 55.73% to $23.1 million in 2024, then crashed by 78.93% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Other Operating Expenses are $4.9 million (Q4 2025), $26.7 million (Q3 2025), and $6.9 million (Q2 2025).